AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 38(2), 1988, pp. 237-243
Copyright © 1988 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sexton, J. D.
Right arrow Articles by Neill, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sexton, J. D.
Right arrow Articles by Neill, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHLOROQUINE
*MEFLOQUINE
*QUININE
Medline Plus Health Information
*Malaria

Parasitologic and Clinical Efficacy of 25 and 50 MG/KG of Chloroquine for Treatment of Plasmodium falciparum Malaria in Rwandan Children

John D. Sexton*, Philippe Deloron*, Laurent Bugilimfura{dagger}, Augustin Ntilivamunda{dagger} AND Maryanne Neill{dagger},{ddagger},
* Malaria Branch, Division of Parasitic Diseases, Center for Infectious Diseases,
and{ddagger} International Health Program Office, Centers for Disease Control, Atlanta, Georgia,
and{dagger} Combatting Childhood Communicable Diseases Program, Ministry of Health, Kigali, Rwanda

The standard chloroquine treatment for Plasmodium falciparum malaria is 25 mg (base)/kg (C25) given over 3 days. In Rwanda, 50 mg/kg (C50) administered over 6 days has been recommended by the Faculty of Medicine, Ministry of Health. The present study compared clinical and parasitological efficacy and side effects of C25 and C50 in children ≤5 years of age. In vitro studies with chloroquine, mefloquine, pyrimethamine, and quinine were also performed. Ninety children were given a 3-day treatment of C25 and 48 a 5-day treatment of C50. Cases were followed for a total of 15 days (D0 to D14). At day 14, 73% of the C25 and 67% of the C50 children were still parasitemic, but the mean geometric parasite density had decreased by at least 96% in both groups. Clinically, 44 C25 and 12 C50 children had fever on day 0; by day 14 only 4 (9%) C25 and 4 (33%) C50 children still had fever. Side effects were found to be minimal. The chloroquine in vitro tests corroborated the in vivo findings. P. falciparum was found to be quite sensitive to mefloquine and quinine, but showed a high (59%) resistance to pyrimethamine.

Accepted for publication August 11, 1987.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Society of Tropical Medicine and Hygiene.